Investors

Investors arrow News Releases
Print E-mail
News Releases

All Releases  
View Summary Peregrine Pharmaceuticals to Report Third Quarter FY 2010 Financial Results
Mar 5, 2010
PDF 7.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Present at Two Upcoming Investor Conferences
Mar 1, 2010
PDF 7.5 KB Add to Briefcase
View Summary New Scientific Publication Highlights Long-Term Survival of Brain Cancer Patients Treated With Peregrine Pharmaceuticals' Cotara(R)
Feb 11, 2010
PDF 11.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Present at the 12th Annual BIO CEO and Investor Conference
Feb 2, 2010
PDF 7.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
Jan 11, 2010
PDF 9.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Present at the OneMedForum 2010 Finance Conference
Jan 6, 2010
PDF 7.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
Dec 10, 2009
PDF 26.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results
Dec 3, 2009
PDF 7.4 KB Add to Briefcase
View Summary Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Dec 2, 2009
PDF 11.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Nov 18, 2009
PDF 12.5 KB Add to Briefcase
View Summary New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Cancer Model
Nov 10, 2009
PDF 11.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
Nov 4, 2009
PDF 12.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements
Nov 3, 2009
PDF 9.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Oct 21, 2009
PDF 10.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
Oct 19, 2009
PDF 10.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes Effect
Oct 19, 2009
PDF 9.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
Oct 16, 2009
PDF 10.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
Oct 7, 2009
PDF 14.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Oct 5, 2009
PDF 10.9 KB Add to Briefcase
View Summary Avid Bioservices Becomes U.S. West Coast Partner of Boehringer Ingelheim's Global Production Alliance Network for Biologic Contract Manufacturing Services
Sep 21, 2009
PDF 11.5 KB Add to Briefcase
Showing 1-20 of 371 Page: 1 2 3 ... 19  Next 20
= add release to Briefcase
Stock Information  
NASDAQ:PPHM
$3.53   + 0.03
Mar 10, 2010
3:59 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
Shareholder Tools  
 
 
© 2003/2010 Peregrine Pharmaceuticals Inc., All Rights Reserved   Disclaimer | Safe Harbor